Trial Profile
Phase II open label study of PTK787/ZK222584 [vatalanib] in adults patients with refractory or relapsed diffuse large cell lymphoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2014
Price :
$35
*
At a glance
- Drugs Vatalanib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 13 Aug 2012 Planned end date changed from 1 Nov 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 17 Aug 2011 Planned end date changed from 1 Nov 2010 to 1 Nov 2011 as reported by ClinicalTrials.gov.
- 15 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.